New Breast Cancer Drug Trial Results to Debut in Dec.
Preliminary Phase 1 findings for the selective CDK4 inhibitor AVZO-023 will be shared with the medical community.
Updated on Oct. 30, 2026 in Health

Avenzo Therapeutics is set to present preliminary Phase 1 data from its ORION-1 study at the 2026 San Antonio Breast Cancer Symposium. The presentation on December 9, 2026, will feature findings on the investigational selective CDK4 inhibitor AVZO-023 in patients with HR+/HER2- breast cancer.
Why it matters
Researchers are investigating new approaches to target tumor proliferation while potentially reducing the side effects associated with broader kinase inhibition. This study explores the role of selective CDK4 targeting in combination with fulvestrant for managing hormone receptor-positive breast cancer.
Avenzo Therapeutics will share preliminary Phase 1 results from the ORION-1 trial, which evaluates the selective CDK4 inhibitor AVZO-023 combined with fulvestrant. These initial findings represent early-stage data regarding the experimental treatment for HR+/HER2- breast cancer.
The players
Avenzo Therapeutics
A biotechnology company focused on developing targeted oncology therapies, including novel kinase inhibitors for breast cancer.
The details
AVZO-023 is designed to selectively inhibit CDK4 signaling pathways while sparing CDK6, a distinction aimed at improving the therapeutic profile of breast cancer treatments. The ORION-1 study is also investigating a combination therapy involving AVZO-023, AVZO-021, and fulvestrant to address tumor growth and potential resistance mechanisms. Detailed findings will be available via poster presentation number P1-4-13 at the symposium.
Timeline
December 8-11, 2026: The San Antonio Breast Cancer Symposium takes place.
December 9, 2026: Preliminary results for AVZO-023 are presented.
Health Landscape
The development of selective CDK inhibitors represents an evolving effort to improve upon existing standards for hormone receptor-positive breast cancer treatment. This study follows the pattern established by the San Antonio Breast Cancer Symposium for sharing clinical trial developments.
This early-stage study provides insight into potential new drug mechanisms for individuals managing HR+/HER2- breast cancer. These findings are foundational and should be discussed with an oncologist to understand how they may relate to current treatment options.
The takeaway
The upcoming presentation highlights ongoing efforts to refine targeted therapies for hormone receptor-positive breast cancer. Patients are encouraged to track clinical trial updates through their oncology team and stay informed on how new, selective kinase inhibitors may shape future care conversations.
What happens next
The preliminary results for AVZO-023 will be presented as a poster at the Henry B. Gonzalez Convention Center on December 9, 2026.
Further reading
Learn more about evolving treatment standards in our Cancer section.
Source note: This article includes information reported by Firstwordpharma.




